Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Avigdor

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Transplantation and Cellular Therapy|May 24, 2026
Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignanciesMarina Gomez-Llobell, Silvia Escribano Serrat, Maria Bromberg, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
Journal of the National Cancer Institute|September 28, 2021
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesCarlos A Garcia-Prieto, Lorea Villanueva, Alberto Bueno-Costa, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Transplantation and Cellular Therapy|May 24, 2026
Impact of ASTCT toxicity grading system on outcomes after CAR-T for mature B-cell malignanciesMarina Gomez-Llobell, Silvia Escribano Serrat, Maria Bromberg, et al.
The Lancet. Oncology|December 15, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 studyAsher Chanan-Khan, Paula Cramer, Fatih Demirkan, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Blood Advances|August 15, 2025
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaXavier Deschênes-Simard, Maria Bromberg, Sean M Devlin, et al.
Journal of the National Cancer Institute|September 28, 2021
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesCarlos A Garcia-Prieto, Lorea Villanueva, Alberto Bueno-Costa, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Transplantation and Cellular Therapy|April 6, 2026
Outcomes of Salvage Therapy After Early-Line CD19 CAR-T Failure in Large B-Cell LymphomaSilvia Escribano Serrat, Andrew Ip, Jaime Sanz, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Pageof 12